Initial findings regarding a blood-based mRNA signature for identifying pancreatic ductal adenocarcinoma (PDAC) and distinguishing intraductal papillary mucinous neoplasms (IPMN) are slated for presentation in San Diego.
BERKELEY, Calif. and , Jan. 14, 2026 — Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostics firm focused on early cancer detection, is pleased to confirm its attendance at the forthcoming American Association for Cancer Research (AACR) 2026 Annual Meeting. This esteemed conference is scheduled for April 17 to 22, 2026, in San Diego, California. Hosted by the American Association for Cancer Research, this leading event convenes scientists, medical professionals, and industry executives globally to disseminate pioneering cancer research and investigate novel strategies in oncology.
During the AACR meeting, the Company plans to unveil the outcomes of its verification study. This study assessed a concise, proprietary blend of blood-derived mRNA biomarkers alongside an AI-powered modeling technique, developed to distinguish PDAC from non-cancerous conditions, such as IPMNs, within a cohort of 30 subjects.
Additional information will be made available in the digital Proceedings of the AACR.
The Company anticipates presenting these study results at AACR, with the goal of transforming pancreatic cancer screening methodologies and aiding in the global reduction of cancer-related mortality.
For ongoing updates, please follow us:
About Mainz Biomed NV
Mainz Biomed creates molecular genetic diagnostic solutions ready for market, addressing life-threatening diseases. The Company’s primary offering is ColoAlert®, a precise, non-invasive, and user-friendly diagnostic test for the early detection of colorectal cancer. ColoAlert® is currently sold throughout Europe. The Company is presently conducting its eAArly DETECT 2 clinical study, a precursor to its crucial FDA study for regulatory clearance in the US. Mainz Biomed’s pipeline of product candidates also features PancAlert, an early-stage screening test for pancreatic cancer that utilizes real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in both blood and stool specimens. To discover more, visit or connect with us on , and .
For media inquiries concerning Mainz Biomed:
MC Services AG
Maximilian Schur / Simone Neeten
+49 211 529252 20
For investor relations questions, please reach out to
Forward-Looking Statements
Certain declarations within this press release constitute “forward-looking statements” as defined by the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements can be identified by terms like “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project,” along with similar expressions that forecast or indicate future occurrences or trends, rather than historical facts. These forward-looking statements are based on the current assessment of available information and are subject to various risks and uncertainties. Consequently, prudence is advised when relying on these statements. Due to both identified and unidentified risks, actual outcomes may diverge significantly from the Company’s expectations or forecasts. The following elements, among others, could lead to actual results differing materially from those outlined in these forward-looking statements: (i) failure to achieve anticipated development and related objectives; (ii) modifications in applicable laws or regulations; (iii) the impact of the COVID-19 pandemic on the Company and its existing or prospective markets; and (iv) other risks and uncertainties detailed herein, as well as those risks and uncertainties periodically discussed in other reports and public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Further information regarding these and other factors that might influence the Company’s expectations and projections can be found in its initial SEC filings, including its annual report on Form 20-F filed on March 31, 2025, and its mid-year report on Form 6-K filed on September 26, 2025. The Company’s SEC filings are publicly accessible on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is solely based on information currently at Mainz Biomed’s disposal and is valid only as of its creation date. Mainz Biomed assumes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether due to new information, future developments, or otherwise, except as mandated by law.
